Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 12:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 398 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hypertrophic Clear all

Conditions: Cardiomegaly
Interventions: MEK162; Drug
Lead sponsor: Array Biopharma, now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Danon Disease
Interventions: RP-A501; Genetic
Lead sponsor: Rocket Pharmaceuticals Inc.; Industry
Eligibility: 8 Years and older · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 3
States / cities: La Jolla, California • Boston, Massachusetts • Philadelphia, Pennsylvania

Conditions: Benign Prostatic Hypertrophy
Interventions: Cetrorelix Pamoate; Drug
Lead sponsor: AEterna Zentaris; Industry
Eligibility: 50 Years and older · Male only
Enrollment: 528 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 56
States / cities: Homewood, Alabama • Huntsville, Alabama • Laguna Hills, California + 49 more

Conditions: Cardiomyopathy
Interventions: Not listed
Lead sponsor: Tenaya Therapeutics; Industry
Eligibility: 0 Years to 18 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 21
States / cities: Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 17 more

Conditions: Muscle Hypertrophy, Muscle Strength
Interventions: Resistance training; Behavioral
Lead sponsor: Auburn University; Other
Eligibility: 18 Years to 30 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Auburn, Alabama

Conditions: Hypertrophic Scar, Burn Scar
Interventions: Luminis ultrapulse fractional ablative carbon dioxide laser; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypertrophic Cardiomyopathy
Interventions: Ranolazine; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: B-cell Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia
Interventions: XmAb13676; Biological
Lead sponsor: Xencor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 10
States / cities: La Jolla, California • Jacksonville, Florida • Atlanta, Georgia + 7 more

Conditions: Peripheral Artery Disease, Coronary Disease, Diabetes and Heart Failure, Dilated Cardiomyopathy, Heart Failure, Renal Artery Stenosis, Pulmonary Hypertension
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 2009
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Muscle Hypertrophy, Healthy and Well-Trained Men and Women
Interventions: Time Restricted Eating, Normal Feeding, Resistance Training, Whey Protein; Other · Dietary Supplement
Lead sponsor: California State University, Fullerton; Other
Eligibility: 18 Years to 35 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Fullerton, California

Conditions: Pain, Postoperative, Tonsillar Hypertrophy, Tonsillitis, Pediatric Sleep Apnea, Sleep-Disordered Breathing
Interventions: Methadone, Fentanyl/Hydromorphone; Drug
Lead sponsor: Duke University; Other
Eligibility: 3 Years to 17 Years
Enrollment: 440 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Scars, Hypertrophic
Interventions: Treatment of hypertrophic scars (Soliton's Rapid Acoustic Pulse (RAP) Device); Device
Lead sponsor: Soliton; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: San Diego, California

Conditions: Healthy Participants
Interventions: Mavacamten; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 158 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 4
States / cities: Miami, Florida • Springfield, Missouri • Austin, Texas

Conditions: Aortic Stenosis, Disorder of Prosthetic Cardiac Valve, Aortic Valve Insufficiency, Mitral Valve Insufficiency, Hypertrophic Cardiomyopathy, Tricuspid Valve Insufficiency
Interventions: Blood Draw; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 21 Years and older
Enrollment: 378 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2020
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Hypertrophic Cardiomyopathy
Interventions: pacemaker implantation, percutaneous transluminal septal ablation (PTSA); Procedure
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Acne Scars - Mixed Atrophic and Hypertrophic
Interventions: MIRIA Laser; Device
Lead sponsor: AVAVA, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: Miami, Florida • Waltham, Massachusetts • New York, New York

Conditions: Myelofibrosis (MF)
Interventions: Ruxolitinib, Navitoclax; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 33
States / cities: Birmingham, Alabama • Cerritos, California • Duarte, California + 27 more

Conditions: Cardiac Glycogenosis, Cardiomyopathy, Hypertrophic, Wolff-Parkinson-White Syndrome
Interventions: ATR 1072; Drug
Lead sponsor: Atrium Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Surgical Procedure, Unspecified, Tonsil Hypertrophy
Interventions: Virtual reality; Other
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 6 Years to 12 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Gaucher Disease
Interventions: Plant cell expressed recombinant glucocerebrosidase (prGCD); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
U.S. locations: 14
States / cities: La Jolla, California • Aurora, Colorado • Coral Springs, Florida + 11 more

Conditions: Healthy Adults (Full Study and Extension Phase), Hypertrophic Cardiomyopathy or Dilated Cardiomyopathy
Interventions: Family History + Whole Genome Sequencing, Family History Only; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 90 Years
Enrollment: 213 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Autoimmune Disease, Lymphatic Disease, Lymphoproliferative Disorder
Interventions: Pyrimethamine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hypertrophic Cardiomyopathy
Interventions: on-pump intracardiac echocardiography; Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy
Interventions: Aficamten, Placebo; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 24
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 20 more

Search by objective public record fields.

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEK162 in Noonan Syndrome Hypertrophic Cardiomyopathy

A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease

Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH)

Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy

Hip Thrust Versus Back Squat Training in Untrained Adults

Pain and Itch Reduction in Burn Scars Treated With Fractional CO2 Laser

Ranolazine for the Treatment of Chest Pain in HCM Patients

Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies

Evaluation of Patients With Known or Suspected Heart Disease

Time-Restricted Eating and Muscle Hypertrophy

Optimization of Pediatric Tonsillectomy to IMprove AnaLgesia

Treatment of Fibrotic Scars With Rapid Acoustic Pulse (RAP) Device

A Study to Evaluate the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants

Biomarkers in Aortic Stenosis - B.A.S.S.

A Comparison of Two Treatments: Pacemaker and Percutaneous Transluminal Septal Ablation for Hypertrophic Cardiomyopathy

The MIRIA Acne Scar Study

A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis

ATR 1072 in Participants With PRKAG2 Syndrome

Virtual Reality as a Perioperative Teaching Tool for Families

Expanded Access Trial of Plant Expressed Recombinant Glucocerebrosidase (prGCD) in Patients With Gaucher Disease

A Pilot Project Exploring the Impact of Whole Genome Sequencing in Healthcare

Pyrimethamine to Treat Autoimmune Lymphoproliferative Syndrome

OPIE in the Thin Interventricular Septum

A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).